Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies With Genetic Alterations of the PI3K/AKT Pathway

Trial Profile

Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies With Genetic Alterations of the PI3K/AKT Pathway

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 19 Oct 2018

At a glance

  • Drugs Miransertib (Primary)
  • Indications Growth disorders; Proteus syndrome
  • Focus Expanded access; Therapeutic Use
  • Sponsors ArQule
  • Most Recent Events

    • 19 Oct 2018 According to an ArQule media release, preliminary data from two patients treated as part of this trial was presented at the American Society of Human Genetics (ASHG) 2018 Annual Meeting.
    • 27 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top